Prio Wealth Limited Partnership’s Mersana Therapeutics MRSN Stock Holding History

Prio Wealth Limited Partnership’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$44.5K	Hold	941	–	–	﹤0.01%	264
2024 Q2	$47.3K	Hold	941	–	–	﹤0.01%	257
2024 Q1	$105K	Hold	941	–	–	﹤0.01%	266
2023 Q4	$54.6K	Hold	941	–	–	﹤0.01%	255
2023 Q3	$29.9K	Hold	941	–	–	﹤0.01%	247
2023 Q2	$77.4K	Hold	941	–	–	﹤0.01%	251
2023 Q1	$96.7K	Hold	941	–	–	﹤0.01%	245
2022 Q4	$138K	Hold	941	–	–	0.01%	246
2022 Q3	$159K	Hold	941	–	–	0.01%	243
2022 Q2	$109K	Hold	941	–	–	﹤0.01%	250
2022 Q1	$94K	Hold	941	–	–	﹤0.01%	262
2021 Q4	$146K	Hold	941	–	–	﹤0.01%	270
2021 Q3	$222K	Hold	941	–	–	0.01%	260
2021 Q2	$320K	Hold	941	–	–	0.01%	231
2021 Q1	$381K	Hold	941	–	–	0.01%	216
2020 Q4	$626K	Hold	941	–	–	0.02%	165
2020 Q3	$438K	Hold	941	–	–	0.02%	177
2020 Q2	$551K	Hold	941	–	–	0.03%	164
2020 Q1	$137K	Hold	941	–	–	0.01%	229
2019 Q4	$135K	Hold	941	–	–	0.01%	256
2019 Q3	$37K	Hold	941	–	–	﹤0.01%	256
2019 Q2	$95K	Hold	941	–	–	﹤0.01%	242
2019 Q1	$123K	Hold	941	–	–	0.01%	237
2018 Q4	$95K	Hold	941	–	–	0.01%	219
2018 Q3	$235K	Hold	941	–	–	0.01%	223
2018 Q2	$420K	Hold	941	–	–	0.02%	178
2018 Q1	$371K	Buy	+941	New	+$372K	0.02%	183

Other funds holding MRSN

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prio Wealth Limited Partnership's MRSN Position: Q3 2024 in Review

Prio Wealth Limited Partnership held its Mersana Therapeutics (MRSN) position steady in Q3 2024 at 941 shares worth $44.5K. The position accounts for ﹤0.01% of the portfolio, ranked #264.

Prio Wealth Limited Partnership first reported a position in MRSN in Q1 2018 and has held it in 27 quarters since. The position peaked at $626K in Q4 2020. 113 funds tracked by Wall St. Rank hold MRSN as of Q3 2024.

Prio Wealth Limited Partnership held 941 shares of Mersana Therapeutics worth $44.5K as of Q3 2024.
Prio Wealth Limited Partnership left its Mersana Therapeutics share count unchanged in Q3 2024.
Mersana Therapeutics made up ﹤0.01% of Prio Wealth Limited Partnership's portfolio in Q3 2024, its #264 holding.
Prio Wealth Limited Partnership first reported a position in Mersana Therapeutics in Q1 2018 and has held it in 27 quarters since.
Prio Wealth Limited Partnership's Mersana Therapeutics position peaked at $626K in Q4 2020.
113 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2024.

Based on Prio Wealth Limited Partnership's 13F filing for Q3 2024, filed 21 Oct 2024.